

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 March 2023 (23.03.2023)



(10) International Publication Number
WO 2023/044094 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/7125 (2006.01)

A61K 31/712 (2006.01) A61K 31/713 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2022/043948

(22) International Filing Date:

19 September 2022 (19.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/246,084 20 September 2021 (20.09.2021) US

(71) Applicant: ALNYLAM PHARMACEUTICALS, INC.

[US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).

(72) Inventor: DEATON, Aimee, M.;

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).

(74) Agent: ZACHARAKIS, Maria, Laccotripe et al.;

McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: INHIBIN SUBUNIT BETA E (INHBE) MODULATOR COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates to modulators, e.g., double stranded RNA (dsRNA) agents, antisense polynucleotide agents, antibodies, guideRNAs that effect ADAR editing, or guideRNAs that effect CRISPR editing, that modulate, e.g., inhibit, the expression and/or activity of inhibin subunit beta E (INHBE). The invention also relates to methods of using such modulators to inhibit expression and/or activity of INHBE and to methods of preventing and treating an INHBE-associated disorder, e.g., metabolic disorder, e.g., metabolic syndrome, in a subject.



WO 2023/044094 A1